Company: CeMM Research Centre for Molecular Medicine
Job title: Principal Investigator
Dr. Winter conducted his postdoctoral studies at the Dana Farber Cancer Institute under the supervision of Jay Bradner. During this time, he developed the first generalizable solution for in vivo protein degradation based on heterobifunctional degraders hijacking the CRBN E3 ligase. Since 2016, he is leading his independent research group, intersecting high-throughput technologies (functional genomics, transcriptomics, proteomics, phenotypic chemical screening) with targeted protein degradation to develop next generation degraders, and to dissect and disrupt gene control mechanisms in health and disease. Georg Winter’s work is recognized by multiple awards such as the Eppendorf Award, and supported by multiple national and international grants, including an ERC Starting grant awarded in 2019.
Genetic Determinants of Targeted Protein Degradation: Resistance and Beyond 10:30 am
Coupling genome-scale CRISPR screens with degrader treatment enables a comprehensive network of cellular effectors required for efficient TPD Scalable mutagenic profiling of 50 key effector genes in hundreds of spontaneously resistant clones points to resistance mechanisms of possible clinical relevance Intersecting functional genomics with structural biology allows determination of key interfacial residues driving ternary complex…Read more
day: Day One